<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01292629</url>
  </required_header>
  <id_info>
    <org_study_id>2010-N251</org_study_id>
    <nct_id>NCT01292629</nct_id>
  </id_info>
  <brief_title>Comparison of the Hoya Surgical Optics (HSO) iSert 251 Posterior Chamber Aspheric Aphakic Intraocular Lens to Historical / Literature Controls.</brief_title>
  <official_title>Comparison of the HSO iSert 251 Posterior Chamber Aspheric Aphakic Intraocular Lens to Historical / Literature Controls.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoya Surgical Optics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoya Surgical Optics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this multi-center clinical trail is to determine the safety and efficacy of
      the iSert 251 for the correction of aphakia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluated the safety and effectiveness of the Hoya Surgical Optics iSert Model 251
      IOL following primary implantation for the visual correction of aphakia in adults in whom the
      cataractous lens has been removed by phacoemulsification. Results from this prospective,
      multicenter clinical trial will be used to support a PMA supplement for the iSert® 251 IOL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>4 to 6 months</time_frame>
    <description>BEST Spectacle-Correction (ETDRS) Distance Visual Acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications and Adverse Events</measure>
    <time_frame>4 to 6 months</time_frame>
    <description>Number of Participants with Complications or Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Aphakia</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Investigational intraocular lens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iSert 251 intraocular lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iSert 251 intraocular lens</intervention_name>
    <description>aphakic intraocular lens</description>
    <arm_group_label>Investigational intraocular lens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have been diagnosed with cataract for which phacoemulsification extraction and
             posterior chamber IOL implantation is indicated

          -  Have clear intraocular media

          -  Have potential Best Corrected Visual Acuity of 20/40 or better

          -  Have preoperative Best Spectacle-Corrected visual acuity of 20/40 or worse

        Exclusion Criteria:

          -  Have ocular pathology or abnormalities that do or are expected to reduce best
             corrected visual acuity in the operative eye during the study period

          -  Are monocular

          -  Have current ocular infection

          -  Are taking systemic steroids or other anti-metabolites

          -  Have previous retinal detachment in the operative eye or expect to require retinal
             laser treatment during the course of the study

        Eligibility criteria not complete. Contact Hoya Surgical Optics, Inc. for more information.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kees den Besten</last_name>
    <role>Study Director</role>
    <affiliation>Hoya Surgical Optics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Schwartz Laser Eye Center</name>
      <address>
        <city>E. Shea Blvd, Suite C101</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katzen Eye Care and Laser Center</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Excellence in Eye Care</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Surgeons of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Health Vision Centers</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2011</study_first_submitted>
  <study_first_submitted_qc>February 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2011</study_first_posted>
  <results_first_submitted>February 11, 2015</results_first_submitted>
  <results_first_submitted_qc>March 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 20, 2015</results_first_posted>
  <last_update_submitted>March 18, 2015</last_update_submitted>
  <last_update_submitted_qc>March 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intraocular lens</keyword>
  <keyword>IOL</keyword>
  <keyword>cataract</keyword>
  <keyword>Hoya</keyword>
  <keyword>surgical</keyword>
  <keyword>optics</keyword>
  <keyword>ocular</keyword>
  <keyword>visual acuity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Aphakia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects who were &gt;50 years of age, either sex, and any race were eligible for this study. Diagnosis of cataracts in one or both eyes.</recruitment_details>
      <pre_assignment_details>Subject’s eligibility was determined at the preoperative visit. All subject met inclusion/exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>iSert 251: iSert 251 Intraocular Lens</title>
          <description>Implantation with the iSert® 251 Intraocular lens</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>iSert® 251 Intraocular Lens</title>
          <description>Population Description: A total of 125 subjects were implanted with the iSert® IOL. Data analysis for baseline characteristics was completed on these 125 subjects.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>A total of 125 subjects were implanted with the iSert® IOL. Data analysis for baseline characteristics was completed on these 125 subjects.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 60 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>61 – 69 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70 – 79 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 80 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity</title>
        <description>BEST Spectacle-Correction (ETDRS) Distance Visual Acuity</description>
        <time_frame>4 to 6 months</time_frame>
        <population>125 subjects enrolled in the study, 121 were examined at the Form 4 and the remaining four (3.2%) subjects missed the Form 4 visit but were examined later. 121 subjects were evaluated for primary and secondary effectiveness and safety outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>iSert 251: iSert 251 Intraocular Lens</title>
            <description>Eligible subjects underwent phacoemulsification cataract extraction surgery and were implanted with the iSert® Intraocular Lens. Study observation was up to 271 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity</title>
          <description>BEST Spectacle-Correction (ETDRS) Distance Visual Acuity</description>
          <population>125 subjects enrolled in the study, 121 were examined at the Form 4 and the remaining four (3.2%) subjects missed the Form 4 visit but were examined later. 121 subjects were evaluated for primary and secondary effectiveness and safety outcomes.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with BSCVA 20/40 or Better at Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with BSCVA 20/40 or Better at Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications and Adverse Events</title>
        <description>Number of Participants with Complications or Adverse Events</description>
        <time_frame>4 to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>iSert 251 Aphakik IOL</title>
            <description>iSert 251: iSert 251 intraocular lens</description>
          </group>
        </group_list>
        <measure>
          <title>Complications and Adverse Events</title>
          <description>Number of Participants with Complications or Adverse Events</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4-6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>iSert 251: iSert 251 Intraocular Lens</title>
          <description>Subjects who underwent phacoemulsification cataract extraction surgery who were implanted with the iSert aphakic intraocular lens.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kees den Besten, Vice President Global Quality, Regulatory Affairs, and Clinical Research</name_or_title>
      <organization>Hoya Surgical Optics, Inc.</organization>
      <phone>+65 6681 0025</phone>
      <email>kees.denbesten@HOYA.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

